Proactive Investors - Run By Investors For Investors

Zelda Therapeutics to use Federal Government R&D tax rebate of $769,000 to drive clinical trials

The Australian-based bio-pharmaceutical company has also formed a strategic relationship with European medicinal cannabis group HAPA Medical BV to access HAPA’s EU-GMP grade manufacturing capabilities.
Zelda Therapeutics to use Federal Government R&D tax rebate of $769,000 to drive clinical trials
Shares last traded at 4.4 cents a share

Zelda Therapeutics Ltd (ASX:ZLD) will use the $769,000 cash refund it received under the Federal Government’s R&D Tax Incentive Scheme to accelerate current clinical trials as well as a pre-clinical program.

The R&D Tax Incentive Scheme is an Australian Government program where companies receive cash refunds of 43.5% if eligible expenditure is on research and development.

READ: Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO sessions

The refund positions Zelda well as it advances its current:

  • Human clinical trial program – focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and
  • Pre-clinical research program – examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

 

 

The company conducts this work in partnership with world-leading researchers and organisations such as Complutense University in Spain, Curtin University in Western Australia, the Telethon Kids Institute in Perth, the University of Western Australia and the Children’s Hospital of Philadelphia in the United States.

In March 2019 Zelda was awarded a patent to detect breast cancer, which details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2 (types of protein).

HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

A WeedMD greenhouse
January 22 2019
WeedMD produces cannabis and cannabis oil for both the medical and adult-use markets
FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
A cannabis plant shown next to an oil-based product
April 24 2019
THC is executing a medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use